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treatment effects using multivariate meta-analyses. Results: Given the variation 
in analysis populations and timing of outcome assessment across RCTs, a limited 
number of studies were considered sufficiently similar for meta-analyses. For NP, 
a positive relationship between microbiological eradication and cure (correlation 
coefficient of 0.84; 95%CI 0.07, 0.98; 5 studies) and a negative relationship between 
eradication and mortality (-0.86; 95%CI -0.97, -0.34; 7 studies) were observed. For 
cIAI, clinical outcome was used as a proxy measure for microbiological eradication, 
but no correlation with mortality was identified. No relationship was observed for 
cUTI either. ConClusions: Relationships between treatment effects in terms of 
eradication and clinical cure and between eradication and mortality were identified 
for NP. For cIAI and cUTI, the relationship between microbiologic eradication and 
treatment effects is unclear based on available study level RCT evidence. Given the 
great variation between studies and several uncertain findings, evaluations using 
patient level data are recommended.
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objeCtives: Human Immunodeficiency Virus (HIV) has become a chronic man-
ageable disease after the advent of combination antiretroviral therapy (ART). Since 
launching of ART, the numbers of patients enrolled in to ART are increasing in 
developing countries like India. In this study we aim to analyze clinical and immu-
nological outcomes of ART in a community care hospital. Methods: A retrospec-
tive cohort study was conducted by including 800 ART naive HIV infected adult 
patients initiated on ART. All patients survived in ART centre at Mysore, India for 12 
months from January 2013 to January 2014 were included. Parameters like weight, 
hemoglobin, WHO clinical stage and CD4 count were collected from medical records 
before initiation and after completion of 12 months ART. Outcomes of ART were 
analyzed by paired T- test using SPSS version 21. Results: A statistically signifi-
cant improvement was observed for weight [53.9 (11.9) to 58.2 (32.6) kg; P = 0.002] 
and CD4 count [206.6 (177.4) to 331.1 (220.5); P = 0.001] at the end of 12 months of 
ART treatment. Whereas, marginal improvement in hemoglobin [11.94 (4.3) to 11.98 
(5.7) g%; P = 0.91] was observed, though it was not statistically significant. Also 
observed a significant increase in percentage of patients in WHO clinical stage I 
(64-82%) and decrease in number of patients in stages II (13-14%), III (5-2%) and IV 
(18-12%). ConClusions: The improvement in weight and CD4 count are indirect 
parameters of > 95% medication adherence and of sustained viral suppression. The 
optimal outcome would have been all patients in WHO clinical stage I or II and none 
in III and IV, but in this study 2% and 12% of patients continued to be in stage III and 
IV respectively. This may be due to development of opportunistic infections such as 
tuberculosis which is endemic in India.
PIN4
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objeCtives: Oritavancin (ORI) is a lipoglycopeptide with bactericidal activity 
against Gram-positive bacteria including MRSA. This analysis evaluated efficacy 
and hospital length of stay of ORI for patients with acute bacterial skin and skin 
structure infections (ABSSSI) who received care in the SOLO program in the US 
and Eastern Europe. Methods: SOLO I and II were identically-designed compara-
tive, multicenter, double-blind, randomized studies to evaluate the efficacy and 
health care resource utilization (HRU) of single 1200 mg dose IV ORI versus 7-10 
days of twice-daily intravenous (IV) vancomycin (VAN) for the treatment of ABSSSI. 
SOLO protocols were amended (Amendment 2) to allow outpatient treatment at the 
investigator’s discretion. Efficacy and HRU of treatment were assessed in inpatient 
and outpatient settings. Efficacy for the European Medicines Agency (EMA) was 
investigator-assessed clinical cure 7-14 days after end of treatment. HRU endpoints 
were hospitalization rate and length of stay (LOS) in days if the patient was hos-
pitalized. Results: In the combined studies, 1959 patients were in the modified 
intent-to-treat (mITT) population; 1,172 patients (60%) received a portion of their 
care in as inpatients; 202 patients were treated in Eastern European countries (EUC: 
Russian Federation, Romania and Ukraine) and 1,165 were treated in the US. Clinical 
cure rates were similar for ORI and VAN in both regions (86.1% and 84.2% in EUC, 
80.6% and 77.9% in the US. The average LOS (ALOS) in the EUC was longer than in 
the US (14.9 and 14.7 vs. 6.0 and 6.4 days). ConClusions: Clinical cure rates at PTE 
were similar between ABSSSI patients who received a single dose of ORI or 7-10 days 
of VAN in SOLO, but the ALOS in the US was considerably shorter than in Eastern 
Europe. Using oral or long-acting antibiotic treatments may reduce the numbers of 
inpatient IV antibiotic administrations, which has been associated with reduced 
LOS in other studies.
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objeCtives: Vaccination has proven to be an efficient preventive strategy against 
influenza infection. Each year, two genetically distinct influenza B lineages co-
circulate. Current trivalent influenza vaccines (TIVs) contain only one influenza 
B and two influenza A strains, but vaccine mismatch are frequent due to the 
difficulty to predict which B lineage will predominate during the next epidemic. 
objeCtives: Inadequate control over emesis during cancer chemotherapy can 
adversely affect patient’s quality of life, delay the subsequent chemotherapy cycle 
and may lead to poor adherence to treatment. This study was conducted to assess 
appropriateness of anti-emetics use in the management of chemotherapy induced 
nausea and vomiting. Methods: A prospective observational study was conducted 
for a period of 6 months at private cancer hospital. Medical records of the patients 
on chemotherapy were reviewed and patients were interviewed to assess the pre-
scribing pattern of anti-emetics and its appropriateness. Chemotherapy regimen 
and given anti-emetics for each patient were recorded and reviewed with respect 
to National Comprehensive Cancer Network (NCCN) guidelines for anti-emesis to 
ensure the appropriateness of drug use. Results: Of 346 patients’ record reviewed, 
majority (74%) of them were prescribed with drugs which are highly emetogenic 
followed by 17% of them with moderately emetogenic and 9% of them with low 
emetogenic potential. Unlike 30% of patients who were added with NK-1 recep-
tor antagonist (NK1RA) either in oral or intravenous formulation, majority (n= 184, 
70.76%) of the patients receiving highly emetogenic regimen were placed on com-
bination of 5-HT3 antagonist and corticosteroids without adding NK1RA for pre-
vention of acute and delayed emesis. Majority patients (64%) receiving moderately 
emetogenic regimen were prescribed with combination of 5-HT3 antagonist and 
corticosteroids and remaining received combination of metoclopramide with cor-
ticosteroids. Most of the patients (82%) receiving low emetogenic regimen were 
prescribed with combination of metoclopramide and corticosteroids and remain-
ing were prescribed with 5-HT3 antagonist and corticosteroid. Over all, selection of 
anti-emetic regimen was inappropriate for 32% (n= 112) patients. Dosage, frequency 
and duration of anti-emetic use were inappropriate in 18%, 38% and 8% respec-
tively. ConClusions: Most of the patients received same anti-emetic regimen for 
highly emetogenic and moderately emetogenic agents. Cost was the limiting factor 
to choose an appropriate anti-emetic regimen.
INfeCtIoN – Clinical outcomes Studies
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objeCtives: Cobicistat, a CYP3A inhibitor, is a novel, alternative pharmacoen-
hancer to ritonavir. A fixed-dose combination once-daily formulation that contains 
darunavir and cobicistat has been developed to simplify dosing and to enhance 
patient convenience. This analysis compared the virological response of a cobi-
cistat-boosted versus a ritonavir-boosted darunavir QD regimen by testing for non-
inferiority. Methods: Patient level data on 800mg QD darunavir treatment from 3 
phase 3 trials (GS-216-0130, TMC114-C211, TMC114-C229) were combined for analy-
sis of virological response at Week 48, using the Snapshot algorithm methodology. 
Patients were HIV-1-infected treatment-naïve or -experienced with no darunavir 
resistance-associated mutations at baseline. The non-inferiority margin was set 
at 0.531 on the odds-ratio (OR) scale, which corresponded to a 12% non-inferiority 
margin on the risk-difference scale, assuming an 80% response rate.  Multiple logis-
tic regression was used to adjust for differences in baseline patient characteristics 
(age, gender, race, baseline CD4+ T-cell counts, baseline HIV-1 RNA, HIV disease 
status, and previous antiretroviral use) and level of darunavir treatment adher-
ence. A sensitivity analysis was performed on data from patients with viral load<50 
copies/mL according to time to loss-of-virological response (TLOVR) algorithm at 
week 48. Results: Treatment with darunavir/cobicistat(800/150mg QD, n=313) was 
non-inferior to darunavir/ritonavir (800/100mg QD, n=637). Unadjusted virological 
response rates were 81% and 78%, respectively. The adjusted odds ratio [95% CI] 
for virological response comparing darunavir/cobicistat with darunavir/ritonavir at 
week 48 was 0.878 [0.576, 1.339] (Snapshot). The 95% CI lower boundary was above 
the defined non-inferiority margin. The sensitivity analysis gave similar results: 
TLOVR OR=0.803 [0.534, 1.208]. ConClusions: This adjusted analysis of pooled 
phase 3 data of an 800mg once-daily darunavir dose showed that darunavir/cobi-
cistat has non-inferior efficacy compared with darunavir/ritonavir.
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objeCtives: Infections caused by Gram-negative bacteria, including nosocomial 
pneumonia (NP), complicated urinary tract infections (cUTI), and complicated 
intra-abdominal infections (cIAI), have been increasing. Although microbiological 
eradication is on the presumed causal path from antibiotic susceptibility to clini-
cal success, other factors impact clinical success rates as well. This study assessed 
the relationship between microbiological eradication and clinical outcomes for NP, 
cUTI, and cIAI based on randomized controlled trial (RCT) evidence. Methods: 
A systematic literature search identified RCTs (25 NP trials, 10 cUTI, 28 cIAI, and 1 
cUTI & cIAI trial) that met the following criteria: Adult patients with cUTI, cIAI, or 
NP; Gram-negative bacteria present in at least a fraction of the population; treat-
ment including coverage of Gram-negative bacteria; any measure of microbiological 
eradication and either clinical response, cure or mortality. RCTs with information on 
both eradication and clinical outcome were selected to estimate their relationship to 
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The main aim of this systematic review was to analyse and compare the clinical effi-
cacy and safety of metronidazole, vancomycin and fidaxomicin in the therapy of C. 
difficile infection. Methods: Systematic review and meta-analysis of the literature 
using Bayesian mixed treatment comparison. Results: Nine studies were included 
in the mixed-treatment comparison. Our meta-analysis showed that clinical cure 
was more likely with fidaxomicin compared to vancomycin and metronidazole, 
however the differences were not significant. (odds ratios [95% CI]: fidaxomicin 
vs. vancomycin 1.19 [0.82-1.66]; vancomycin vs. metronidazole 1.69 [0.93-2.82] and 
fidaxomicin vs. metronidazole 2.00 [0.99-3.66]). Fidaxomicin therapy was signifi-
cantly more efficacious than vancomycin and metronidazole in endpoints of recur-
rence (odds ratios [95% CI]: fidaxomicin vs. vancomycin 0.47 [0.33-0.65]; vancomycin 
vs. metronidazole 0.91 [0.44-1.69] and fidaxomicin vs. metronidazole 0.43 [0.19-0.85]) 
and sustained cure (odds ratios [95% CI]: fidaxomicin vs. vancomycin 1.77 [1.35-
2.28]; vancomycin vs. metronidazole 1.49 [0.92-2.30]; and fidaxomicin vs. metroni-
dazole 2.64 [1.50-4.35]. There was no significant difference between fidaxomicin, 
vancomycin and metronidazole in safety endpoints. ConClusions: Fidaxomicin 
was the most efficacious therapeutic alternative in lowering the rate of recurrent 
C. difficile infections.
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objeCtives: To conduct mixed treatment comparisons (MTC) to compare sime-
previr, a new generation NS3/4A protease inhibitor, with boceprevir and telaprevir 
(all in combination with PR) and with PR alone in treatment-naïve and treatment-
experienced genotype 1 HCV infected patients. These MTC results were used to 
inform the cost-effectiveness model for simeprevir and to prepare submissions to 
HTA agencies (including NICE). Methods: A Bayesian MTC based on a systematic 
literature review was conducted. Outcomes of interest included sustained virologic 
response (SVR) rates, incidence of anaemia and rash and discontinuation due to 
adverse events (AEs) rates. Networks were based on treatment-, dose- and duration-
specific nodes. Q80K-positive patients were excluded from simeprevir arms for the 
analysis of SVR rates in line with EMA label considerations for simeprevir. Subgroup 
analyses were conducted to investigate heterogeneity, based on METAVIR scores, 
sub-genotypes 1a/1b and prior response. Results: Simeprevir was associated with 
higher SVR rates than PR alone in both treatment-naive (OR [95%CrI]: 4.83 [3.50-
6.70]) and treatment-experienced patients (ORs: 9.02 [5.54-15.01]) for simeprevir 
12+PR 24/48 weeks and 8.73 [5.42-14.19] for simeprevir 12 +PR 48 weeks). Compared 
to telaprevir and boceprevir, SVR rates tended to be higher for simeprevir with 
odds-ratios ranging from 1.27 [0.81-2.00] to 2.61 [1.44-4.74] in treatment-naïve and 
from 1.04 [0.78-1.38] to 1.74 [0.84-3.61] in treatment-experienced patients. In terms 
of safety, the risks of anaemia and discontinuations due to AEs were lower for 
simeprevir compared to PR alone, telaprevir and boceprevir. The risk of rash was 
lower for simeprevir compared to telaprevir, and similar compared to PR alone and 
boceprevir. ConClusions: This MTC in genotype 1 HCV patients suggests a similar 
or better efficacy and a better tolerability profile for simeprevir compared to tel-
aprevir and boceprevir both in treatment-naïve and treatment-experienced patients.
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objeCtives: Widespread uncontrolled use of antibiotics contributes to the develop-
ment of microbial resistance. Study of antibiotic consumption by ATC / DDD method 
in terms of DDDs/1000 inhabitants / day (DID) is one of the ways to control the 
resistance development rate. Macrolide antibiotics are widely used for treatment 
of infectious diseases; therefore, their consumption needs control. Methods: Data 
on packed macrolides consumption in Ukraine, Russia and Kazakhstan, provided 
by analytical companies researching pharmaceutical market - “Pharmstandard” 
and IMS Health, has been used for the study. Results: Comparing the figures in 
Ukraine, Russia and Kazakhstan, the largest consumption (in DID) was observed in 
Russia, Ukraine was in the second place, Kazakhstan was in the third place, during 
2010-2012. However, the data were not significantly different; indices were 1.496, 
1.445 and 1.356 DID respectively in 2012. The analysis results showed that azithro-
mycin was leading as of consumption in DID in 2010-2012. Every year, the consump-
tion of this preparation increases. Compared to 2010, in 2012 the azithromycin DID 
consumption index increased for 21.4% and amounted to 0.7931 DID. This means 
that 5.8% of the population of Ukraine takes one course of azithromycin (5 days) 
during the year. Growth of azithromycin consumption is associated with its high 
efficacy. It is accumulated in most tissues and organs, it has the least side effects 
and provides high compliance; it is used in pediatric practice from an early age. 
Azithromycin consumption rate in Russia and Kazakhstan increases every year as 
well. Calculations showed that 2.12% of the population took a course of azithromy-
cin in Russia during 2012; in Kazakhstan, this index equaled 4.59%. ConClusions: 
The analysis showed that, macrolide antibiotics consumption level in Ukraine, 
Kazakhstan and Russia within the study period was comparable.
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Recently licensed quadrivalent influenza vaccines (QIVs) containing a strain from 
each B lineage should address these issues, but their impact still needs to be 
estimated. Our study assesses retrospectively what would have been the public 
health benefit of routinely vaccinating the US population with QIV instead of 
TIV. Methods: We developed a dynamic compartmental model able to account 
for interactions between influenza B lineages (natural or vaccine-induced). The 
model simulates influenza dynamics for the period 2000-2014, to account for the 
long-term impact of infection and vaccination. Age-structured population dynam-
ics, vaccine efficacy (VE) per strain, and weekly ramp-up of vaccination coverage 
are modelled. Sensitivity analyses were performed on VE, duration of immunity, 
levels of vaccine-induced cross-protection between B strains. Results: Assuming 
a cross-protection of 70% of the matched VE, the model predicts that QIV would 
have prevented on average 15% more B-lineages cases. Elderly people (65+yo) and 
young seniors (50-64yo) benefit the most from QIV with 21% and 18% reduction 
of B cases respectively in those age groups. Reducing the cross-protection esti-
mate of the matched VE to 50%, 30%, and 0% improves the relative benefit of QIV 
to 25%, 30%, and 34% fewer B cases in the US. ConClusions: Using a realistic 
retrospective framework, with real-life vaccine mismatch, our analysis shows 
that routine vaccination with QIV has the potential to substantially reduce the 
number of influenza infections, even with relatively conservative estimates of 
TIV induced cross-protection.
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objeCtives: Human Papillomavirus (HPV) is the primum movens both in the eti-
opathogenesis of invasive cervical cancer and in other neoplastic malignant and 
benign lesions. HPV vaccination was implemented in Italy since 2008. The aim of 
this study is to evaluate the burden of HPV-related diseases and the effect of cur-
rent HPV-vaccination strategy in Italy. Methods: A multistate morbidity mortality 
model was developed in order to estimate the infection process on a theoretical 
cohort of Italian women. The conceptual Markov process was adapted considering 
the data available in national and international literature. 7 states (Health, Genital 
Warts, Grade 1 and Grade 2/3 cervical intraepithelial neoplasia, Cervical Cancer, 
Death for Cervical Cancer and death for other cause) and 18 transition probabili-
ties were considered. A 5-years incidence rate class was extrapolated and Rogers 
and Ledent method transformation was used to convert rates into probabilities. 
Vaccination efficacy was carried out by literature modelling review and based to 
the coverage rate of the two anti-HPV vaccines available in Italy. Life expectancy 
(ex), Quality Adjusted Life Years (QALYs), Disability Adjusted Life Years (DALYs) and 
Attributable risk (AR) were estimated for no intervention and vaccination strategies 
scenarios. Results: The preliminary results show that for a theoretical cohort of 
100,000 Italian women the e0 is equal to 84.31 years. With the present HPV vac-
cination strategy the e0 increase to 84.36 (+0.05) years. However, considering the 
HPV-related diseases altogether, the QALYs increase from 83.9 for no intervention 
to 84.1 for Vaccine prevention approach (+0.2QALYs). DALYs decrease of 0.6 thanks 
to Vaccination (2 DALYs for no intervention cohort vs 1.4 DALYs lived for vaccinated 
cohort). AR is equal to 0.08 and 0.29 for population and not vaccinated respec-
tively. ConClusions: The model demonstrates that, if we consider different HPV-
related diseases, Italian HPV vaccination strategy has significantly effect on health 
gains for female population.
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objeCtives: To evaluate the efficacy and safety of ceftriaxone and levofloxacin 
in treating community-acquired pneumonia and provide references for clinical 
application. Methods: This was a systematic review. Data were collected from 
literature (randomized controlled trails) published from January 2003 to January 
2014 through searching databases both at home and abroad, such as CNKI, 
WanFang Data, VIP, PubMed, Science Direct, Springer, Ovid, Wiley-Blackwell and 
The Cochrane Library (Issue1, 2014). Both qualitative analysis and quantitative 
analysis were conducted. Quantitative analysis (meta-analysis) was performed 
by RevMan 5.2. Results: Nine studies were included, involving 2233 patients. Of 
these, six studies (553 patients) met meta-analysis criteria. The results of meta-
analysis were clinical effective rates (RR= 0.90, 95%CI, P= 0.002), and adverse events 
rates (RR= 0.70, 95%CI, P= 0.22). The result of qualitative description as follows: 
one prospective, randomized study showed success rate were 89% in the ceftri-
axone group and 96% in the levofloxacin group; one multicenter retrospective 
study showed the mortality of the two groups were 3.1% and 2.0%, the length of 
hospital stay (LOS) were 5.5±3.5 days and 4.8±2.9 days respectively, with no sig-
nificant difference found between groups; the other retrospective study showed 
ceftriaxone could shorten LOS since it had a trend toward earlier switch to oral 
therapy. ConClusions: In general, current evidence shows that the efficacy 
for the treatment of community-acquired pneumonia of levofloxacin is superior to 
ceftriaxone, there were no significant difference in the incidence of adverse reaction.
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objeCtives: C. difficile is the leading cause of antibiotic associated infectious noso-
comial diarrhoea. A limited number of new pharmaceutical products have been 
developed and registered in past decades for the treatment of C. difficile infection. 
